Neofect, a specialist in rehabilitation treatment equipment, plans to launch a new service that enables patients to receive diagnosis and treatment at home from remote doctors and therapists, in the United States by the end of this year.
For the Korean market, however, Neofect abandoned its service plan since the remote treatment is not legal here in Korea.
3 Billion also plans to release in May a genetic analysis service that allows users to check more than 4,000 types of rare disorders at once. The company, however, deleted Korea from the list of countries where it can offer its service. The nation's life science ethics law limits the types of disorders that can be subject to genetic analysis and checkup only to 12.
According to the Science and Technology Policy Institute, the number of biotech-related regulations among the 15,312 regulations registered in the Regulation Reform Committee stood at 1,163 as of 2014. Among these, 553 regulations are related with the healthcare business.
The bill to approve remote medical treatment failed to pass the National Assembly over the past ten years due to opposition from the medical service industry. A number of outdated regulations also still remain unchanged, including one concerning the development of artificial intelligence-based medical software.